Advances in Thoracic Oncology: A Multi-disciplinary Approach to Lung Cancer

Dear Colleagues,

The landscape and treatment options for lung cancer for both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) is rapidly evolving. Patients are living longer due to advances in thoracic radiation therapy, immunotherapy, targeted therapy, and thoracic surgery. This Special Issue on the advances in thoracic oncology will provide a current update and overview, encompassing the role of these advances for both SCLC and NSCLC. We are pleased to include leading researchers that will provide a comprehensive summary as well as new evidence for the following topics: role of local therapy for brain metastases and prophylactic cranial irradiation in NSCLC and SCLC, thoracic re-irradiation for isolated thoracic recurrences, cardiac toxicities from thoracic radiotherapy and mitigation strategies, neoadjuvant therapy and peri-operative therapy for operable stage III NSCLC, oligometastatic and oligoprogressive lung cancer and the role of local therapy, personalized treatment approaches for frail or older patients with lung cancer, emerging systemic options (targeted therapy and immunotherapy) in lung cancer, and finally advances in the treatment paradigm for unresectable stage III NSCLC. Indeed, these are exciting times as treatment continues to improve for our patients with lung cancer.

Dr. Percy Lee
Dr. Jyoti Malhotra
Dr. Arya Amini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• small cell lung cancer (SCLC)
• non-small cell lung cancer (NSCLC)
• thoracic radiotherapy
• neoadjuvant therapies
• oligometastatic disease
• targeted therapy
• immunotherapy
• unresectable stage III NSCLC
• brain-directed radiation therapy small cell lung cancer (SCLC)
• non-small cell lung cancer (NSCLC)
• thoracic radiotherapy
• neoadjuvant therapies
• oligometastatic disease
• targeted therapy
• immunotherapy
• unresectable stage III NSCLC
• brain-directed radiation therapy